| Chemical & Physical Properties | |
|---|---|
| CAS Number | 103060-53-3 |
| Catalog No. | 2A-9049964 |
| Chinese Name | 达托霉素 |
| Synonyms | Daptomycin; Deptomycin; Cubicin; LY146032; CUBICIN DAPTOMYCIN; Cidecin |
| Molecular Formula | C72H101N17O26 |
| Molecular Weight | 1620.67 |
| Purity | 98.00 |
| Density | 1.5±0.1 g/cm3 |
| Boiling Point | 2078.2±65.0 °C at 760 mmHg |
| Melting Point | 202-204?C |
| Appearance | liquid |
| Water Solubility | methanol: soluble5mg/mL |
| Storage Condition | Store at -20°C |
| Application | Daptomycin is a lipopeptide antibiotic with rapid in vitro killing activity against Gram-positive bacteria. |
| PubChem ID | 7848143 |
| MDL Number | MFCD28968054 |
| SMILES | O=C(NCC(N[C@H](CCCN)C(N[C@@H](CC(O)=O)C(N[C@H](C)C(N[C@@H](CC(O)=O)C(NC1)=O)=O)=O)=O)=O)[C@@H](NC([C@H](CC(O)=O)NC([C@@H](CC(N)=O)NC([C@H](CC2=CNC3=C2C=CC=C3)NC(CCCCCCCCC)=O)=O)=O)=O)[C@@H](C)OC([C@H](CC(C4=C(N)C=CC=C4)=O)NC([C@@]([C@H](C)CC(O)=O)([H])NC( |
| InChI | 1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35?,36-,37?,43+,44+,45+,46+,47+,48+,49+,50-,60+,61?/m1/s1 |
| InChI Key | DOAKLVKFURWEDJ-OFNKPWESSA-N |
| NACRES Code | NA.76 |
| UNSPSC | 51102829 |
| MSDS | msds/49964_1_103060_53_3.pdf |
| Bioactivity | Daptomycin is a lipopeptide antibiotic with rapid in vitro bactericidal activity against gram-positive organisms. Related Catalog Signaling Pathways >> Anti-infection >> Bacterial Research Areas >> Infection In Vitro Daptomycin has excellent in-vitro inhibitory and bactericidal activity against nafcillin-susceptible and resistant staphylococci (MIC90 less than or equal to 0.5 mg/L) and against enterococci (MIC90 less than or equal to 2.0 mg/L). Daptomycin is more active than vancomycin against the majority of isolated tested. With the exception of trimethoprim-sulphamethoxazole, daptomycin is the most active agent in vitro against enterococci, and is the most active against nafcillin-resistant staphylococci. Daptomycin and vancomycin show a marked increase in MIC when the inoculum is increased from 105 to 107 cfu/mL[1]. Daptomycin is effective within a very narrow range of drug concentrations (from 0.125 to 2.0 tLg/mL) and is more active than other agents tested against S. faecalis[2]. Daptomycin inhibits the formation of these nucleotide-linked intermediates[3]. In Vivo At a dose of 10 mg/kg given twice daily, daptomycin reduces the number of organisms per kidney significantly compared with that in infected untreated controls within 48 h after the initiation of therapy. At 20 mg/kg given once a day, daptomycin is less effective but reduces colony counts significantly after 4 days of therapy, and its activity is comparable to that of vancomycin or vancomycin-gentamicin given twice daily[2]. Animal Admin Inocula containing 109 CFU/mL are prepared from an 18-h brain heart infusion broth culture. The exact number in each inoculum is subsequently determined by the standard serial 10-fold dilution agar pour plate technique. Animals are challenged intravenously with a 1.0-mL inoculum. This inoculum is known to infect the renal medulla of normal rats. Twenty-four hours later the animals are divided into eight groups and are given either saline only (controls) or antibiotic therapy initiated with Daptomycin at 10 mg/kg (Daptomycin10), Daptomycin at 20 mg/kg (Daptomycin20), Daptomycin10 plus gentamicin at 1.5 mg/kg, vancomycin at 20 mg/kg, vancomycin at 20 mg/kg plus gentamicin at 1.5 mg/kg, ampicillin at 30 mg per rat per injection, and ampicillin at 30 mg per rat plus gentamicin at 1.5 mg/kg. Animals receive Daptomycin20 once daily; all other drugs are administered twice daily. Vancomycin and Daptomycin are given subcutaneously; ampicillin and gentamicin are given intramuscularly. Drugs are administered for up to 13 days. References [1]. Benson CA, et al. Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms. J Antimicrob Chemother. 1987 Aug;20(2):191-6. [2]. Miniter PM, et al. Activity of LY146032 in vitro and in experimental enterococcal pyelonephritis. Antimicrob Agents Chemother. 1987 Aug;31(8):1199-203. [3]. Allen NE, et al. Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032. Antimicrob Agents Chemother. 1987 Jul;31(7):1093-9. Chemical & Physical Properties Density 1.5±0.1 g/cm3 Boiling Point 2078.2±65.0 °C at 760 mmHg Melting Point 202-204?C Molecular Formula C72H101N17O26 Molecular Weight 1620.671 Flash Point 1210.7±34.3 °C Exact Mass 1619.710327 PSA 702.02000 LogP -4.07 Appearance of Characters colorless to faint yellow Vapour Pressure 0.0±0.3 mmHg at 25°C Index of Refraction 1.638 InChIKey DOAKLVKFURWEDJ-OFNKPWESSA-N SMILES CCCCCCCCCC(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(N)=O)C(=O)NC(CC(=O)O)C(=O)NC1C(=O)NCC(=O)NC(CCCN)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NCC(=O)NC(CO)C(=O)NC(C(C)CC(=O)O)C(=O)NC(CC(=O)c2ccccc2N)C(=O)OC1C Storage condition Store at -20°C Water Solubility methanol: soluble5mg/mL |
| Use of | Daptomycin is a lipopeptide antibiotic with rapid in vitro bactericidal activity against gram-positive organisms. Properties Name daptomycin Synonym More Synonyms Daptomycin Biological Activity Description Daptomycin is a lipopeptide antibiotic with rapid in vitro bactericidal activity against gram-positive organisms. Related Catalog Signaling Pathways >> Anti-infection >> Bacterial Research Areas >> Infection References [1]. Benson CA, et al. Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms. J Antimicrob Chemother. 1987 Aug;20(2):191-6. [2]. Miniter PM, et al. Activity of LY146032 in vitro and in experimental enterococcal pyelonephritis. Antimicrob Agents Chemother. 1987 Aug;31(8):1199-203. [3]. Allen NE, et al. Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032. Antimicrob Agents Chemother. 1987 Jul;31(7):1093-9. Chemical & Physical Properties Molecular Formula C72H101N17O26 Exact Mass 1619.710327 PSA 702.02000 LogP -4.07 Appearance of Characters colorless to faint yellow Index of Refraction 1.638 InChIKey DOAKLVKFURWEDJ-OFNKPWESSA-N |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information United Nations classification: inconsistent with United Nations classification standards UN number: not specified |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| N,N'-Bis[[4-(2-propen-1-yloxy)phenyl]methylene]-1,4-benzenediamine | 102947-88-6 | 2A-9049950 |
| 2,5-Dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)benzenamine | 103015-84-5 | 2A-9049953 |
| 6-Methoxy-1-aminoindan hydrochloride | 103028-80-4 | 2A-9049955 |
| 6-Bromo-2-methyl-4-quinolinol | 103030-28-0 | 2A-9049956 |
| Ethyl 3-(pyridin-2-ylamino)propanoate | 103041-38-9 | 2A-9049959 |
| D-Prallethrin | 103065-19-6 | 2A-9049965 |
| DL-3-Amino-3-(2-methoxyphenyl)propionic acid | 103095-63-2 | 2A-9049969 |
| 4-[4-(Dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)benzonitrile | 103146-25-4 | 2A-9049971 |
| 4-[4-(Dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)benzonitrile hydrobromide | 103146-26-5 | 2A-9049972 |
| Pranlukast | 103177-37-3 | 2A-9049974 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS